Litigating the Hype: The Lung Health Institute Class Action and Its Implications
Authors:
- Mark AlonzoMAMark Alonzo
- Bambi J. GrilleyBGBambi J. Grilley
- Daniel J. WeissDWDaniel J. Weiss
- Laertis IkonomouLILaertis Ikonomou
Open Access
- 3 May 2026
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 28 (10)
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Litigation of unlicensed US stem cell productsCell Stem Cell, 2025
- Effective regulatory responses to predatory stem cell markets in Australia and CanadaCell Stem Cell, 2024
- International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven productsCytotherapy, 2023
- Weighing up the evidence used by direct-to-consumer stem cell businessesStem Cell Reports, 2021
- The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventionsCell Stem Cell, 2021
- ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 updateStem Cell Reports, 2021
- Pay-to-Participate Trials and Vulnerabilities in Research Ethics OversightJAMA, 2019
- How to Peddle Hope: An Analysis of YouTube Patient Testimonials of Unproven Stem Cell TreatmentsStem Cell Reports, 2019
- Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventionsCytotherapy, 2018
- US stem cell clinics, patient safety, and the FDATrends in Molecular Medicine, 2015